Evidence map›Paper›PMID 38560469›Full record

ArticlePeerJ2024

Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway.

Xiaosheng Jin, Weijing Jin, Guoping Li, Jisheng Zheng, Xianrong Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Effects of remote ischemic preconditioning and/or erythropoietin on lung injury induced by skeletal ischemia reperfusion: role of the NLRP3 inflammasome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiaosheng JinPulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Weijing JinDepartment of Neonatology, Hangzhou Children's Hospital, Hangzhou, China.
Guoping LiPulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Jisheng ZhengPulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Xianrong XuPulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Tongde Hospital of Zhejiang Province · CNHangzhou Children's Hospital · CN

Funding

Basic Public Welfare Research Program of Zhejiang Province
6 · The paper itself

Abstract

Background: The purpose of the present study was to investigate the effect of erythropoietin (EPO) on lung ischemia-reperfusion injury (LIRI). Methods: Sprague Dawley rats and BEAS-2B cells were employed to construct an ischemia-reperfusion (I/R)-induced model Results: It was observed that lung tissue damage, cell apoptosis and the expression of BAX and caspase-3 were higher in the LIRI model Conclusion: EPO could effectively improve LIRI, which might be related to the activation of the FGF23/FGFR4/p-ERK1/2 signaling pathway.

Indexed as

ErythropoietinReperfusion InjuryAnimalsbcl-2-Associated X ProteinCaspase 3Epoetin AlfaHumansIschemiaLungMAP Kinase Signaling SystemProto-Oncogene Proteins c-bcl-2RatsRats, Sprague-DawleyReceptor, Fibroblast Growth Factor, Type 4Signal Transductionbcl-2-Associated X ProteinCaspase 3Epoetin AlfaEPO protein, humanErythropoietinerythropoietin, ratFGFR4 protein, humanProto-Oncogene Proteins c-bcl-2Receptor, Fibroblast Growth Factor, Type 4ErythropoietinFGF23Lung ischemia-reperfusion injury

Identifiers

PMID38560469
PMCPMC10981413
OpenAlexW4393226886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.